Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty telehealth platform offering prescription medications, mental health support, and personal care products.

Investors look for heavily shorted stocks either to bet on a further decline in the company's value or to profit from a potential short squeeze.

Tempus AI and Hims & Hers are riding healthcare IT growth, but diagnostics scale and consumer demand set different upside paths.

Carnegie Investment Counsel lifted its holdings in Hims and Hers Health, Inc. (NYSE: HIMS) by 25.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 303,909 shares of the company's stock after acquiring an additional 61,560 shares during the period.

Hims and Hers Health, Inc. (NYSE: HIMS - Get Free Report) CFO Oluyemi Okupe sold 23,090 shares of Hims and Hers Health stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $35.72, for a total transaction of $824,774.80. Following the completion of the transaction, the chief financial officer

Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Let's dive in.

Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.

HIMS deepens its subscription-led model with new care verticals, diagnostics and global expansion to boost retention.

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.